Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2022 08:09 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease (GvHD) is...
March 25, 2022 08:03 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe

Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial...
March 23, 2022 16:19 ET | Source: Novartis Pharma AG

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive...
March 14, 2022 02:15 ET | Source: Novartis Pharma AG

Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce

Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics Respiratory diseases are leading...
March 13, 2022 19:00 ET | Source: Novartis Pharma AG

Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection

Children with three copies of SMN2 treated presymptomatically achieved age-appropriate milestones, including standing and walking; required no ventilatory or feeding tube support; and had no serious,...
March 04, 2022 09:19 ET | Source: Novartis Pharma AG

Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire

Les actionnaires approuvent la 25e augmentation consécutive du dividende qui passe à CHF 3.10 (+3,3%) par action pour 2021; représentant un rendement de 3.9%1 et une distribution du free cash-flow...
March 04, 2022 09:19 ET | Source: Novartis Pharma AG

Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut

Die Aktionäre genehmigen die 25. Dividendenerhöhung in Folge auf CHF 3.10 (+3,3 %) pro Aktie für 2021; dies entspricht einer Rendite von 3.9 %1 und einer Ausschüttung von rund 57 % des freien...
March 04, 2022 09:19 ET | Source: Novartis Pharma AG

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Shareholders approve 25th consecutive dividend increase to CHF 3.10 (+3.3%) per share for 2021; representing a 3.9% yield1 and approximately 57% payout of free cash flowShareholders confirm Dr. Joerg...
February 18, 2022 01:15 ET | Source: Novartis Pharma AG

Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine

Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for...
February 02, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis: a enregistré, en 2021, une croissance du chiffre d’affaires net à un chiffre dans le milieu de la fourchette, une expansion de la marge et une avancée du robuste pipeline

Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du 4e trimestre en hausse de +6% (tcc1, +4% USD) et résultat opérationnel core croissant de +12% (tcc1, +9% USD) Innovative...